Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5669935 | 0.90 | MEN1 (0.47) | MMP2MMP13POLBALDH1A1CYP1A2 | |
| SCHEMBL5670448 | 0.90 | MEN1 (0.47) | MMP2MMP13POLBALDH1A1CYP1A2 | |
| SCHEMBL5670753 | 0.87 | MMP3 (0.38) | MMP2MMP13POLBALDH1A1MMP3 | |
| SCHEMBL5670609 | 0.85 | ADAM10 (0.46) | MMP2MMP13ALDH1A1HSD17B10MMP3 | |
| SCHEMBL5670613 | 0.85 | ADAM10 (0.46) | MMP2MMP13ALDH1A1HSD17B10MMP3 | |
| SCHEMBL5669604 | 0.84 | MMP2 (0.41) | MMP2MMP13ALDH1A1HSD17B10MMP3 | |
| SCHEMBL5671594 | 0.84 | ADAM10 (0.45) | MMP2CHRM4ALDH1A1MMP3CYP1A2 | |
| SCHEMBL5670514 | 0.84 | ADAM10 (0.45) | MMP2CHRM4ALDH1A1MMP3CYP1A2 | |
| SCHEMBL5670595 | 0.81 | RBP4 (0.50) | MMP2MMP13CYP2C19 | |
| SCHEMBL5670318 | 0.79 | ADAM17 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276507-A1 | Hydroxamate sulfonamides as cd23 shedding inhibitors | CELLTECH R&D LIMITED (GB) | 2006-12-07 | — | — | US | disclosed |
| EP-1648868-B1 | HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS | CELLTECH R&D LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276507-A1 | Hydroxamate sulfonamides as cd23 shedding inhibitors | CD2, CD22, NEU3 | MMP2 264/4885MMP13 29/4885CHRM4 3869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.